Dextrose Injection Market is estimated to be valued at USD 6.14 Bn in 2026 and is expected to reach USD 9.05 Bn by 2033, growing at a compound annual growth rate (CAGR) of 5.7% from 2026 to 2033.
| Report Coverage |
Report Details |
| Base Year: |
2025 |
Market Size in 2026: |
USD 6.14 Bn |
| Historical Data for: |
2020 To 2024 |
Forecast Period: |
2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: |
5.70% |
2033 Value Projection: |
USD 9.05 Bn |
Dextrose injection contain source of water and calories, and is capable of inducing diuresis depending on the clinical condition of the patient. Dextrose injections are sterile, non-pyrogenic, and does not contain bacteriostatic or antimicrobial agents. It is intended for intravenous administration. This intravenous solution is indicated for use in adults and pediatric patients as sources of calories and water for hydration. Dosage of dextrose injection is dependent upon the age, weight, and clinical condition of the patient as well as laboratory determinations.
Market Dynamics
Increasing launches and approval of novel products, increasing adoption of inorganic growth strategies such as collaboration and acquisition by key players operating in the market and rising demand for dextrose for first-aid treatment as instant nutrition therapy in critical care are expected to drive the growth of global dextrose injection market over the forecast period. For instance, in July 2015, B. Braun Medical Inc. received the U.S. Food and Drug Administration approval for 70% Dextrose for Injection in a 2L flexible container.
Key features of the study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global dextrose injection market based on the following parameters - company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
- Key companies covered as a part of this study include Pfizer Inc., Amphastar Pharmaceuticals Inc., Shangai Haixin group Co. Ltd., Seqirus GmbH, Baxter International Inc., Shandong Qidu Pharmaceutical, Sanctus drugs and pharmaceuticals Pvt., Hospira Inc., B Braun Medical Ltd., Aurobindo Pharmaceuticals Ltd., and SteriMAx Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global dextrose injection market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global dextrose injection market
Market Segmentation
- By Product Type
- 5% Dextrose Injection
- 10% Dextrose Injection
- 50% Dextrose Injection
- 70% Dextrose Injection
- Others
- By Application
- First-aid Treatment
- Sports
- Trophotherapy
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Dextrose Injection Market, By Region
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
- Key Players
- Pfizer Inc
- Amphastar Pharmaceuticals Inc
- Shangai Haixin group Co Ltd
- Seqirus GmbH, Baxter International Inc
- Shandong Qidu Pharmaceutical
- Sanctus drugs and pharmaceuticals Pvt
- Hospira Inc., B Braun Medical Ltd
- Aurobindo Pharmaceuticals Ltd
- SteriMAx Inc